Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00937677 · ClinicalTrials.gov registry record
Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study
A clinical trial, sponsored by University at Buffalo.
- Completed
- Registry status
- 85
- Enrollment target
NCT00937677: Completed study, sponsored by University at Buffalo.
NCT00937677 is a clinical trial that has completed, run by University at Buffalo. The registered enrollment target is 85 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00937677 has completed, sponsored by University at Buffalo.
- COMPLETED
- Registry status
- 85 participants
- Enrollment target
Study Summary
The primary objective of this study is to define the effect of Tysabri in patients with relapsing-remitting (RR) multiple sclerosis (MS) over 2 years. The investigators will also explore the extent of remyelination in MS patients treated with Tysabri over 2 years. A secondary objective of this study is to investigate differences in the capacity for remyelination between patients who do or do not respond to Tysabri monotherapy during the same 24 months. A tertiary objective of this study is to monitor Tysabri effect in MS antiphospholipid antibodies positive and MS antiphospholipid antibodies negative patients and to determine perfusion differences according to the antiphospholipid antibodies positivity status.
Interventions
- DRUG Tysabri
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2007-11 |
| Est. Completion | 2010-11 |
What the finished NCT00937677 record still lists
NCT00937677 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 85 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Tysabri is the first listed.
NCT00937677 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00937677 about?
NCT00937677 is a clinical study titled "Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study". The primary objective of this study is to define the effect of Tysabri in patients with relapsing-remitting (RR) multiple sclerosis (MS) over 2 years. The investigators will also explore the extent of remyelination in MS patients treated with Tysabri over 2 years. A secondary objective of this stud...
What is the current status of trial NCT00937677?
This trial is currently completed. The enrollment target is 85 participants. The study started on 2007-11. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00937677?
The interventions under investigation include: Tysabri (DRUG).
Who is sponsoring clinical trial NCT00937677?
This trial is sponsored by University at Buffalo, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia